31-45 of 696
DESTINY-Breast11 and Neoadjuvant Care in HER2-Positive Breast Cancer
On the Frontlines of Metastatic Breast CancerDESTINY-Breast11 and Neoadjuvant Care in HER2-Positive Breast Cancer
Jules Cohen, MD
Modern Approaches to Long-Term Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerModern Approaches to Long-Term Metastatic Breast Cancer Care
Charles Turck, PharmD, BCPS, BCCCP
Adam Brufsky, MD, PhD
Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Project Oncology®Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Pavani Chalasani, MD, MPH
Kristina Fanucci, MD, MHS
Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
Project Oncology®Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
Jennifer Caudle, DO, FACOFP
Maxwell Llyod, MD
New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Clinician's RoundtableNew Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Preparing for Parenthood in Psoriasis: Closing Gaps in Family Planning Support
On the Frontlines of PsoriasisPreparing for Parenthood in Psoriasis: Closing Gaps in Family Planning Support
- advertisement
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Pavani Chalasani, MD, MPH
Timothy Yap, MBBS, PhD, FRCP
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Seth Wander, MD, PhD
Tracking Tumor Resistance in Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerTracking Tumor Resistance in Metastatic Breast Cancer Care
Ryan Quigley
Megan Kruse, MD
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Pavani Chalasani, MD, MPH
Erica L. Mayer, MD, MPH
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Pavani Chalasani, MD, MPH
Erica L. Mayer, MD, MPH
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Casey Cosgrove, MD
- advertisement
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Brian Slomovitz, MD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
